Diaceutics PLC

Good afternoon and welcome to the Diocetix PLC Final Results Investor presentation. Throughout this recorded presentation, investors will be in listen-only mode. Questions are encouraged and they can be submitted at any time using the Q&A tab situated on the right-hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it is appropriate to do so. Before we begin, I would like to submit the following poll, and I would now like to hand you over to the team of Diocetics PLC. Good afternoon to you.

Good afternoon, everybody, and welcome to today's call hosted by Diocetics to discuss the company's full year 2024 results issued earlier today. My name is Simon Ghilan, and I manage Diocetics' investor relations program. On the call today to discuss the results are Ryan Keeling, the Chief Executive Officer of Diocetics, and Nick Roberts, the company's CFO. Before I hand you over to Ryan for his formal remarks, I would draw your attention to the forward-looking statement slide in our presentation, which is on screen now and also available to download at InvestorMeetsCompanies and Diastetics.com. At this time, I will now turn the call over to Ryan Keeling. Ryan, go ahead, please.

Thank you, Simon, and thank you all for joining us today. Good afternoon and good morning to those of you joining us from the US. i'm delighted to report on what was a great year in 2024 for diastetics and the format of today is i'll talk you through some top lines then i'm going to hand you over to nick to take a deeper dive into some of the financials and then i'll come back and do a bit of a refresh on on the overall value proposition of the business and i'll also take the opportunity to talk a little bit about 2025 and some of the the observations we have in the market particularly at a macro level Just zooming us back then to 24. For those of you who have followed us or indeed are new to the story, the story of Diasectics is one of a journey and one of business transformation. And we feel through 24, we've moved the needle on most of the KPIs that are really indicating the the direction of travel for our business not as toward high recurring revenue significant arr proportion increased revenue um earnings also quality of revenue and and really talk to that business transformation that we are seeing enabled by our data enabled by our tech and more recently enabled by uh what we feel is a very appropriate use of ai in the business Just going through some of the specifics, we are at the end of the 2024, so the end of our two-year investment cycle in the business. Just to remind you, at the back end of 22, we had funds available to the tune of around 20 million. We wanted to invest around 8 million of that in the business, really to enable scale. and to secure future growth in the business. We believe we've executed well against that two year program in a disciplined way. Nick will talk to the specifics of that, but we feel we already see the return on investment and the exceptional performance in 2024 is to an extent part of the delivery on that 8 million that we've invested over the last two years. we continue to grow the platform and and scale the capabilities there i talked a little bit about how we're leveraging ai we as other businesses in the space are in an era where we can benefit from a technology that is absolutely transformative in terms of what we can do with our data what we can do with the products and ultimately how we can impact the lives of patients remember the purpose is a strong north star for this business And our ability to bring new and novel product, which we have done through the last 12 months is really important. And AI is right at the core of that. As we go from using natural language processing, which is where we were with AI two or three years ago, now to producing our own agentic AI models to really reach that next best action and do more with what we already have in the business is incredibly exciting. We continue to expand our business and our team, and we invest in that key talent, particularly in the US. Through the last 12 months, we have hired at a senior level in the US. We have brought a significant number of new VPs into the business. largely focused on commercial activities. We're also opened our US HQ and we have continued to build our US sales team, again, making some significant inroads into our most significant market. terms of dxrx signal that is our lead product i'll talk more about that and i have a use case to show you later for those not familiar with it but suffice to say it continues to go from strength to strength and last year we identified over 600 000 patients in our data that we ultimately provided back to our pharma customers this is 600 000 patients that may not have had the opportunity to be treated with the optimal treatment for their disease. And we believe we're playing a key part in educating physicians around what the next best action is for those patients. We continue to grow with our customers. Last year, we secured three new multi-year enterprise-wide engagements with a total ARR of 4.3 million. Those enterprise deals symbolize our increased embeddedness with our customers. We won't have them with every customer, but as we get more scaled and ultimately closer to our customers, we believe we'll own more of those in the coming year and beyond. PMX is a product that we had a soft launch of last year. It is effectively an end to end commercialization solution. An easy way for you to think about PMX is it's a solution that is ultimately reaching everything we've built in the business to date. That is our data, our technology, our engagement solutions, our marketing stack and the right amount of analytics and expertise in the terms and form of advisory and ultimately client management. all come together to provide an end-to-end solution. Very exciting for us and a key part of our growth plans for the business is extracting more revenue per brand. And we've shown with our first PMX deal in 24 how we've gone from an average of 400K per year per brand to potentially over 3 million. Very exciting journey for the business. We're now working with 18 of the top 20 global pharma companies. and that is a an excellent client list for us to have the only two we're not working with for our indigenous chinese farmer and and we don't have plans to to do any inroads into that market at this time but suffice to say we are well established and growing in those top 18 pharma and and are very excited about the opportunity there And I'll touch on it again, just given the importance. We really have moved into an execution phase now for this business. We've scaled the business. We've built the data. We've built the expertise and the people. We've built the platform. We'll continue to evolve an exciting roadmap there. But the days of significant build and development and R&D in the business are behind us. We'll continue to innovate, as I say, but not to the same extent as we were and be very much customer driven and customer led going forward. the US market will remain a key focus of ours. I'll talk a bit about the macro environment there in a few slides time. But suffice to say, we are very excited about the journey we're on in the US and the building of the team there is really already driving growth for us. With that, I'm going to pause and I'm going to pass over to Nick to give you a run through some operational and financial highlights.